Beta Bionics, Inc.
corporate_fare Company Profile
Beta Bionics, Inc. (NASDAQ:BBNX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 27 items for BBNX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-27, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for BBNX spans 10-Q, 8-K, 424B5, FWP.
Recent high-impact activity:
- Beta Bionics Q3 Sales Up 30% to $35.5M; Loss Widens to $24.4M, Cash at $373.6M
- Beta Bionics Q3 Sales Up 30% to $35.5M; Guidance Raised, 3D Intelligence 510(k) Withdrawn
- Beta Bionics Q3 Sales Up 30% but Losses Widen; 3D Intelligence 510(k) Withdrawn
- Beta Bionics Plunges 37% on Safety Disclosure; Securities Fraud Class Action Filed
- Beta Bionics Partners with Senseonics to Integrate iLet and mint with Eversense 365
Financial Snapshot
Short Interest & Short Volume
3.94 days to coverFINRA reported short interest of 4,980,771 shares in BBNX as of the October 30, 2026 settlement, a 28.0% decrease from the prior period — about 3.9 days to cover at its recent average daily volume. On November 20, 2026, 54.9% of BBNX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BBNX, detected from its recent SEC filings · based on capital-structure filings through 2026-09-16.
Offering Upsized to $150M · Pre-Funded Warrants Added
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →